Methods of sustained treatment of fistulas in crohn's disease with chimeric anti-TNF antibodies
AssigneeNew York University
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims38
A method of providing sustained reduction of fistulas in Crohn's disease in a human in need thereof, comprising administering to the human at least four doses provided as single or divided 0.5-15 mg/kg doses of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2, for a sufficient period of time to reduce the number of fistulas.
A method of healing mucosa that has been damaged as a result of Crohn's disease in a human in need thereof, comprising administering to the human at least four doses provided as single or divided 0.5-15 mg/kg doses of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2, for a period of time sufficient to heal the damaged mucosa.
A method of reducing steroid administration used in the treatment of Crohn's disease in a human in need thereof, comprising administering to the human at least four doses provided as single or divided 0.5-15 mg/kg doses of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2, for a period of time sufficient to reduce the steroid administration.
A method of reducing hospitalization visits attributed to flare-up of Crohn's disease in a human in need thereof, comprising administering to the human at least four doses provided as single or divided 0.5-15 mg/kg doses of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2, for a period of time sufficient to reduce the hospitalization visits.
Dependencies are inferred from the claim text.